OrSense News
6 articles
growth-positive
FDA Grants Market Clearance for the OrSense NBM200;the First Noninvasive Hemoglobin System Cleared for Use in Blood Donation Centers
OrSense Ltd. has received FDA/CBER 510(K) clearance for its NBM200 non-invasive Hemoglobin measurement device. The clearance allows for the commercialization of the device in all US blood collection centers. The NBM200 is the first non-invasive Hemoglobin measurement device cleared by the FDA/CBER for use in blood banks. It has been used worldwide since 2014 and in the US for over two years by OneBlood. The device provides painless and efficient hemoglobin measurements, eliminating the need for traditional finger pricks. This clearance is expected to improve the blood donor experience and make operations more efficient for blood collection centers.
CustomersPartners
growth-positive
OrSense Delivers First Systems in Mexico
OrSense Ltd. announces the first delivery of its non-invasive Hemoglobin testing systems in Mexico. The NBM200 offers accurate and painless Hb measurements on location, reducing infection risk and environmental impact. OrSense is working closely with Falcón, its distributor in Mexico, to expand its presence in the Mexican market.
Customers
growth-positive
Non-invasive monitoring co OrSense raises $18m
OrSense, a company that develops monitors for non-invasive measurements of key blood parameters, has completed an $18 million financing round led by Israel Healthcare Ventures(IHCV). The funds raised will be used to expand commercialization activities and establish OrSense as the world leader in non-invasive monitoring. OrSense has received FDA clearance for its non-invasive multi-parameter monitor for oxygen saturation and CE approval for the first non-invasive spot and continuous monitor of hemoglobin. The companys customers include blood donation facilities, hospital departments, public screening programs, and outpatient facilities. OrSenses devices have been tested on 8000 subjects in over 40 clinical trials. The investment highlights the continuous support and confidence of the investors.
InvestmentExpand
growth-positive
OrSense completes $6m private financing
OrSense Ltd., a medical device start-up, has received an additional $6 million in funding from investors, including Israel Healthcare Ventures (IHCV), STAR Ventures, and Lewis Trust Group (LTG). The funding will help OrSense establish itself as a world leader in non-invasive glucose monitoring. Carlo Salvi, a director at Teva Pharmaceutical Industries Ltd., has been appointed to OrSenses board of directors. OrSense aims to bring non-invasive glucose monitoring products to the market, reducing the need for needle-stick blood tests. The companys intellectual property portfolio includes 18 granted patents and over 25 additional applications in process. The article was published on February 6, 2006.
Investment
growth-positive
Blood sugar monitor maker OrSense raises $7 million
OrSense, a company that develops noninvasive systems to measure cholesterol, hemoglobin, and glucose in the blood, has raised $7 million in funding. The companys product, the Occlusion Spectroscopy device, is of particular interest to diabetics as it eliminates the need for finger pricking to track blood sugar levels. OrSense has achieved a CE Mark for its product in Europe and is in late stages of clinical trials for FDA approval in the U.S. The company was founded in 1996 and has raised a total of $13 million in funding. It currently has 24 employees.
InvestmentExpand
growth-positive
OrSense raises $8.2 mln from VC funds
OrSense, an Israeli medical device company, has completed an $8.2 million venture capital financing round. The company was also awarded a $1.2 million grant by the Office of the Chief Scientist. OrSense is developing a non-invasive glucose monitor for daily use by diabetics. The financing round reflects the substantial commitment and support of investors in the company. OrSense aims to bring to market the first truly non-invasive sensor of its kind, targeting a market estimated at $3.5 billion per year.
Investment
